Scientific Discovery
从"骨星云"到千年密码From "Bone Nebula" to the Millennium Code
一次偶然的科学发现，开启了骨关节健康研究的新纪元。ABRU1596 的诞生，是传统智慧与现代科学深度融合的典范。A serendipitous scientific discovery opened a new era in bone and joint health research. The birth of ABRU1596 represents a profound fusion of traditional wisdom and modern science.
2021
"骨星云"现象首次发现"Bone Nebula" Phenomenon First Discovered
清华大学、青岛大学、剑桥大学、伦敦大学学院（UCL）专家组成的国际化科研团队，在骨生长机制研究中偶然发现神秘的"骨星云"现象。这一发现突破了骨生长的现有认知边界，为后续研究奠定了创新源头。An international research team comprising experts from Tsinghua University, Qingdao University, University of Cambridge, and University College London (UCL) serendipitously discovered the mysterious "Bone Nebula" phenomenon during bone growth mechanism research. This discovery pushed beyond existing boundaries of bone growth understanding, laying the innovative foundation for subsequent research.
2022 — 2024
三年探索，破解千年之谜Three Years of Exploration, Decoding the Millennium Mystery
团队从《黄帝内经》《本草纲目》等千年经典古籍中筛选数百种与骨关节健康相关的天然良药，运用骨成像技术进行系统评价。历经数百次筛选与活性评价，每克因子凝结数百小时匠心。Drawing from millennia-old classics such as the Yellow Emperor's Inner Canon and Compendium of Materia Medica, the team screened hundreds of natural remedies related to bone and joint health, employing bone imaging technology for systematic evaluation. Through hundreds of screenings and activity assessments, each gram of factor embodies hundreds of hours of craftsmanship.
2024 — 至今Present
ABRU 因子正式确认ABRU Factor Officially Confirmed
从特种桑葚品种"特种乌桑 422"中，发现了具有骨关节保护奇特作用的 ABRU 功能因子。首次为古籍中"桑葚利五脏关节；入肾经，主骨生髓"的记载提供了现代科学证据。From the special mulberry variety "Special Wusang 422," the ABRU functional factor with remarkable bone and joint protective effects was discovered. For the first time, modern scientific evidence was provided for the ancient record that "mulberry benefits the joints of the five viscera; enters the kidney channel, governs bone and produces marrow."
Molecular Mechanism
靶向"金靶点"的分子机制Molecular Mechanism Targeting the "Golden Target"
ABRU1596 的核心机制在于精准靶向骨硬化蛋白（SOST）——调控骨代谢的关键"金靶点"，通过双向调节实现骨代谢的动态平衡。The core mechanism of ABRU1596 lies in precisely targeting Sclerostin (SOST) — the key "golden target" regulating bone metabolism, achieving dynamic balance of bone metabolism through bidirectional regulation.
骨硬化蛋白（Sclerostin, SOST）是由骨细胞分泌的负调控因子，正常情况下通过与 LRP5/6 受体结合，抑制 Wnt/β-catenin 信号通路，从而抑制骨形成。ABRU1596 通过直接结合 SOST，同时激活 Wnt/β-catenin 与 PI3K-AKT 双信号通路。Sclerostin (SOST) is a negative regulatory factor secreted by osteocytes. Under normal conditions, it binds to LRP5/6 receptors, inhibiting the Wnt/β-catenin signaling pathway and thereby suppressing bone formation. ABRU1596 directly binds SOST, simultaneously activating Wnt/β-catenin and PI3K-AKT dual signaling pathways.
1
ABRU1596 直接结合骨硬化蛋白 SOSTABRU1596 directly binds Sclerostin SOST
2
阻断 SOST 与 LRP5/6 受体的相互作用Blocks SOST interaction with LRP5/6 receptors
3
解除对 Wnt/β-catenin 信号通路的抑制Relieves inhibition of the Wnt/β-catenin signaling pathway
激活双信号通路Activates Dual Signaling Pathways
Wnt/β-catenin 通路Wnt/β-catenin Pathway
促进成骨细胞分化Promotes osteoblast differentiation
PI3K-AKT 通路PI3K-AKT Pathway
促进细胞外基质（ECM）沉积Promotes extracellular matrix (ECM) deposition
促进骨形成Promotes Bone Formation
激活 Wnt/β-catenin 信号通路，促进间充质干细胞向成骨细胞分化，加速骨基质矿化，提升骨形成速率。Activates Wnt/β-catenin signaling pathway, promotes mesenchymal stem cell differentiation into osteoblasts, accelerates bone matrix mineralization, and enhances bone formation rate.
抑制骨吸收Inhibits Bone Resorption
下调破骨细胞分化相关基因表达，减少破骨细胞数量与活性，降低骨量流失速度。Downregulates osteoclast differentiation-related gene expression, reduces osteoclast number and activity, and slows bone mass loss.
Experimental Evidence
实验证据Experimental Evidence
从动物实验到细胞实验，从骨密度提升到软骨修复，ABRU1596 的每一份效果都有坚实的科学数据支撑。From animal experiments to cell experiments, from bone density enhancement to cartilage repair, every effect of ABRU1596 is backed by solid scientific data.
抗骨质疏松与促进成骨Anti-Osteoporosis & Osteogenesis Promotion
动物实验 · 骨密度提升Animal · BMD Increase
15%
较对照组，实验周期 28 天后骨密度（BMD）显著提升Significantly increased vs. control after 28 days
来源：动物实验Source: Animal Experiment
动物实验 · 破骨细胞抑制Animal · Osteoclast Inhibition
30%
较对照组，实验周期 28 天后破骨细胞形成显著减少Significantly reduced vs. control after 28 days
来源：动物实验Source: Animal Experiment
动物实验 · 骨小梁面积Animal · Trabecular Area
40%
较对照组，实验周期 28 天后骨小梁面积显著增加Significantly increased vs. control after 28 days
来源：动物实验Source: Animal Experiment
动物实验 · 皮下成骨体积Animal · Subcutaneous Bone Volume
2.5x
较对照组，实验周期 28 天后皮下成骨体积增加Increased vs. control after 28 days
来源：动物实验Source: Animal Experiment
细胞实验数据Cell Experiment Data
细胞实验 · 破骨细胞减少Cell · Osteoclast Reduction
65%
较对照组，添加 72 小时后破骨细胞数量显著减少Significantly reduced vs. control after 72h
来源：细胞实验Source: Cell Experiment
细胞实验 · 基因表达下调Cell · Gene Expression Downregulation
50%
较对照组，添加 72 小时后破骨相关基因表达显著下调Significantly downregulated vs. control after 72h
来源：细胞实验Source: Cell Experiment
逆转衰老关节损伤与软骨保护Reversing Joint Damage & Cartilage Protection
动物实验 · 关节含水量恢复Animal · Joint Water Content
100%
较模型对照组，实验周期 28 天后关节含水量恢复至正常水平Restored to normal vs. model control after 28 days
来源：动物实验Source: Animal Experiment
细胞实验 · 软骨增殖活性Cell · Cartilage Proliferation
30%
较对照组，添加 24 小时后衰老软骨增殖活性显著提升Significantly enhanced vs. control after 24h
来源：细胞实验Source: Cell Experiment
细胞实验 · 增殖活跃中心Cell · Proliferation Centers
200%
较对照组，添加 24 小时后软骨细胞增殖活跃中心显著增加Significantly increased vs. control after 24h
来源：细胞实验Source: Cell Experiment
细胞/动物 · 软骨修复Cell/Animal · Cartilage Repair
显著修复
14 天内退行性关节软骨基本修复，炎性基质较模型对照组显著改善Degenerative cartilage substantially repaired within 14 days; inflammatory matrix significantly improved vs. model control
来源：细胞及动物实验Source: Cell & Animal Experiments
Academic Achievement
学术成果与知识产权Academic Achievements & IP
从《民族药理学杂志》到《欧洲药理学杂志》，从 PCT 国际专利到 SGS 权威认证，ABRU1596 的每一步都经得起学术与市场的双重检验。From Journal of Ethnopharmacology to European Journal of Pharmacology, from PCT international patents to SGS authoritative certification, every step of ABRU1596 stands up to dual scrutiny from academia and the market.
发表期刊Published Journals
《欧洲药理学杂志》European Journal of Pharmacology
European Journal of Pharmacology
European Journal of Pharmacology
国际药理学与药学领域的核心权威 TOP 级期刊A top-tier authoritative journal in international pharmacology and pharmacy
《民族药理学杂志》Journal of Ethnopharmacology
Journal of Ethnopharmacology
Journal of Ethnopharmacology
连接传统医学与现代科学研究的全球权威标杆A global authoritative benchmark connecting traditional medicine with modern scientific research
知识产权Intellectual Property
专利申请受理通知书Patent Application Acceptance Notices
7 项发明专利 + 2 项 PCT 国际专利7 Invention Patents + 2 PCT International Patents
涵盖 ABRU1596 因子的提取技术、制备工艺、质控体系及在骨关节健康领域的应用，构建覆盖全球的知识产权保护网络。Covering extraction technology, preparation processes, quality control systems, and applications in bone and joint health, building a global intellectual property protection network.
权威认证Authority Certifications
SGS / CNAS 双重权威认证SGS / CNAS Dual Authority Certification
通过全球知名机构 SGS 严苛检测，并符合 CNAS 国际认可的实验室标准。生产全过程建立"功效 + 含测"双重质控体系，品质全程可溯。Passing stringent tests by global authority SGS and meeting CNAS internationally recognized laboratory standards. A dual "efficacy + assay" quality control system is established throughout production, with full traceability.
SGS 检测报告SGS Test Reports
技术护城河Technological Moat
AIC"骨星云"可视化技术AIC "Bone Nebula" Visualization
自主研发的可视化定量技术，实现原料生产工艺的精准节点控制，使骨生长过程看得见、评得准。Proprietary visualization and quantification technology enabling precise node control in raw material production processes, making bone growth visible and measurable.
"4 步法多变量质控"体系"4-Step Multi-Variable QC" System
建立高标准的质量控制关键技术体系，确保工艺体系稳定及营养价值可评价。Establishing a high-standard quality control technical system to ensure process stability and nutritional value assessability.
药用级原料品种选育及炮制专有技术Medicinal-Grade Raw Material Breeding & Processing
从种源到成品的全链条品质管控，确保品质全程可溯。Full-chain quality control from germplasm to finished product, ensuring complete traceability.
Contact
联系我们Contact Us
如有学术合作或技术咨询需求，欢迎通过邮件与我们取得联系。For academic collaboration or technical inquiries, please reach out to us via email.